Matthias Beat Wittwer

Dr. Matthias Beat Wittwer

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
CCCarina Cantrill
Carina Cantrill
PCPrasoon Chaturvedi
Prasoon Chaturvedi
CRCaroline Rynn
Caroline Rynn
JSJeannine Petrig Schaffland
Jeannine Petrig Schaffland
IWIsabelle Walter
Isabelle Walter
MWMatthias Beat Wittwer
Matthias Beat Wittwer

5 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MJMing Jiang
Ming Jiang
MHMirjam C. W. Huizenga
Mirjam C. W. Huizenga
JWJonah L. Wirt
Jonah L. Wirt
Janos PalocziJanos Paloczi
Janos Paloczi
AAAvand Amedi
Avand Amedi
MSMario van der Stelt
Mario van der Stelt
Monoacylglycerol lipase (MAGL) regulates endocannabinoid 2-arachidonoylglycerol (2-AG) and eicosanoid signalling. MAGL inhibition provides therapeutic opportunities but clinical potential is limited by central nervous system (CNS)-mediated side effects. Here, we report the discovery of LEI-515, a peripherally restricted, reversible MAGL inhibitor, using high throughput screening and a medicinal chemistry programme. LEI-515 increased 2-AG levels in peripheral organs, but not mouse brain. LEI-515 attenuated liver necrosis, oxidative stress and inflammation in a CCl4-induced acute liver injury model. LEI-515 suppressed chemotherapy-induced neuropathic nociception in mice without inducing cardinal signs of CB1 activation. Antinociceptive efficacy of LEI-515 was blocked by CB2, but not CB1, antagonists. The CB1 antagonist rimonabant precipitated signs of physical dependence in mice treated chronically with a global MAGL inhibitor (JZL184), and an orthosteric cannabinoid agonist (WIN55,212-2), but not with LEI-515. Our data support targeting peripheral MAGL as a promising therapeutic strategy for developing safe and effective anti-inflammatory and analgesic agents.

29 June 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MZMaciej J. Zamek‐Gliszczynski
Maciej J. Zamek‐Gliszczynski
VSVishal Sangha
Vishal Sangha
HSHong Shen
Hong Shen
BFBo Feng
Bo Feng
MWMatthias Beat Wittwer
Matthias Beat Wittwer
ICInternational Transporter Consortium
International Transporter Consortium

4 March 2025 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
GAGiulia Apprato
Giulia Apprato
Giulia CaronGiulia Caron
Giulia Caron
GDGauri Deshmukh
Gauri Deshmukh
DJDiego Jiménez
Diego Jiménez
RHRobin Thomas Ulrich Haid
Robin Thomas Ulrich Haid
MWMatthias Beat Wittwer
Matthias Beat Wittwer
Degraders are an increasingly important sub-modality of small molecules as illustrated by an ever-expanding number of publications and clinical candidate molecules in human trials. Nevertheless, their preclinical optimization of ADME and PK/PD properties has remained challenging. Significant research efforts are being directed to elucidate underlying principles and to derive rational optimization strategies. In this review the authors summarize current best practices in terms of in vitro assays and in vivo experiments. Furthermore, the authors collate and comment on the current understanding of optimal physicochemical characteristics and their impact on absorption, distribution, metabolism and excretion properties including the current knowledge of Drug-Drug interactions. Finally, the authors describe the Pharmacokinetic prediction and Pharmacokinetic/Pharmacodynamic -concepts unique to degraders and how to best implement these in research projects. Despite many recent advances in the field, continued research will further our understanding of rational design regarding degrader optimization. Machine-learning and computational approaches will become increasingly important once larger, more robust datasets become available. Furthermore, tissue-targeting approaches (particularly regarding the Central Nervous System will be increasingly studied to elucidate efficacious drug regimens that capitalize on the catalytic mode of action. Finally, additional specialized approaches (e.g. covalent degraders, LOVdegs) can enrich the field further and offer interesting alternative approaches.

9 September 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AKAlicia M. Kemble
Alicia M. Kemble
BHBenoit Hornsperger
Benoit Hornsperger
IRIris Ruf
Iris Ruf
HRHans Richter
Hans Richter
JBJörg Benz
Jörg Benz
LCLudovic Collin
Ludovic Collin
Chronic inflammation and blood–brain barrier dysfunction are key pathological hallmarks of neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease. Major drivers of these pathologies include pro-inflammatory stimuli such as prostaglandins, which are produced in the central nervous system by the oxidation of arachidonic acid in a reaction catalyzed by the cyclooxygenases COX1 and COX2. Monoacylglycerol lipase hydrolyzes the endocannabinoid signaling lipid 2-arachidonyl glycerol, enhancing local pools of arachidonic acid in the brain and leading to cyclooxygenase-mediated prostaglandin production and neuroinflammation. Monoacylglycerol lipase inhibitors were recently shown to act as effective anti-inflammatory modulators, increasing 2-arachidonyl glycerol levels while reducing levels of arachidonic acid and prostaglandins, including PGE2 and PGD2. In this study, we characterized a novel, highly selective, potent and reversible monoacylglycerol lipase inhibitor (MAGLi 432) in a mouse model of lipopolysaccharide-induced blood–brain barrier permeability and in both human and mouse cells of the neurovascular unit: brain microvascular endothelial cells, pericytes and astrocytes. We confirmed the expression of monoacylglycerol lipase in specific neurovascular unit cells in vitro, with pericytes showing the highest expression level and activity. However, MAGLi 432 did not ameliorate lipopolysaccharide-induced blood–brain barrier permeability in vivo or reduce the production of pro-inflammatory cytokines in the brain. Our data confirm monoacylglycerol lipase expression in mouse and human cells of the neurovascular unit and provide the basis for further cell-specific analysis of MAGLi 432 in the context of blood–brain barrier dysfunction caused by inflammatory insults.

18 March 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MGMaude Giroud
Maude Giroud
BKBernd Kuhn
Bernd Kuhn
SSSandra Steiner
Sandra Steiner
PWPaul Westwood
Paul Westwood
MMMateusz Mendel
Mateusz Mendel
JKJames Keaney
James Keaney